Depressive Disorder/Unipolar Depression: Factors of the Treatment Response in Major Depressive Disorder

Contact name: Michelle Abrams or Jennifer Pacheco

Phone: (310)-825-3351

Fax: (310)-825-7642

Email: jnp42@ucla.edu

Disorder: Depressive Disorder, Unipolar Major Depression

Geographic location: University of California, Los Angeles

Other keywords: depression, EEG, QEEG, Effexor, Venlafaxine, Cymbalta, Duloxetine, Lexapro, Escitalopram, placebo, clinical interaction, antidepressant, brain function, electroencephalogram

Participant compensation: Free medication for up to 8 months, free monitored visits, free thorough diagnostic evaulation

Time commitment required: 10 weeks

Drug trial: Yes

Recruitment end date (approximate): May 8, 2006

Study criteria (i.e., age or gender requirements):
Clinical diagnosis of Unipolar Major Depression

Exclusion criteria:
Substance Abuse, Psychotic Disorder, History of Severe Head Trauma

Brief description of study:
We are using depression symptom measurements and measurements of brain electrical activity (QEEG) to determine what factors may influence whether a patient is likely to show a resposne to antidepressant medication, placebo, or only clinical visits (without the use of pills) during a treatment trial for depression.

Additional information:
There are several clinical trials on the treatment of depression running at our UCLA site. If one does not fit into the criteria for this particular study, he or she may fit into the criteria for another one of our studies. Please visit www.DepressionLA.com for more information or call 310.825.3351 to see if you or someone you know might be eligible.